Study of Diosmin for the Treatment of Digital Ulcers in Systemic Sclerosis
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorPrimus Pharmaceuticals
This study is performed to consider the safety and healing ability of diosmin in patients with systemic sclerosis (scleroderma) and open sores on their fingers (digital ulcers). Two (2) out of three (3) participants will receive active product. The participants will have four (4) visits over eight (8) weeks. Physical exams and photos will be performed. A variety of questions will be asked describing level of pain and lifestyle changes.
Diagnosis of systemic sclerosis (scleroderma)
At least one "active" digital ulcer
Medication for systemic sclerosis unchanged for 30 days
Infection or gangrene in ulcer
Citrus allergy
Unstable heart, kidney, or liver disease
Active infection of any type
Primus Pharmaceuticals
Lead sponsor
KGK Science Inc.
Collaborator